{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:41:35Z","timestamp":1792057295645,"version":"4.4.0"},"reference-count":154,"publisher":"Elsevier BV","issue":"26","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017510","name":"UK Dementia Research Institute","doi-asserted-by":"publisher","award":["UKDRI-1003"],"award-info":[{"award-number":["UKDRI-1003"]}],"id":[{"id":"10.13039\/501100017510","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","award":["201809-2016862"],"award-info":[{"award-number":["201809-2016862"]}],"id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["390857198"],"award-info":[{"award-number":["390857198"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013278","name":"EU Joint Programme \u2013 Neurodegenerative Disease Research","doi-asserted-by":"publisher","award":["JPND2021-00694"],"award-info":[{"award-number":["JPND2021-00694"]}],"id":[{"id":"10.13039\/100013278","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007229","name":"Bijzonder Onderzoeksfonds UGent","doi-asserted-by":"publisher","award":["BOF25IU03"],"award-info":[{"award-number":["BOF25IU03"]}],"id":[{"id":"10.13039\/501100007229","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007229","name":"Bijzonder Onderzoeksfonds UGent","doi-asserted-by":"publisher","award":["BOF22M02"],"award-info":[{"award-number":["BOF22M02"]}],"id":[{"id":"10.13039\/501100007229","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010815","name":"Stiftelsen f\u00f6r Gamla Tj\u00e4narinnor","doi-asserted-by":"publisher","award":["#FO2022-0270"],"award-info":[{"award-number":["#FO2022-0270"]}],"id":[{"id":"10.13039\/100010815","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007436","name":"Erling-Perssons Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["22HLT07"],"award-info":[{"award-number":["22HLT07"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Forschung, Technologie und Raumfahrt","doi-asserted-by":"publisher","award":["01ED2405A"],"award-info":[{"award-number":["01ED2405A"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009550","name":"Hasselt University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009550","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021720","name":"Olav Thon Stiftelsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021720","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2022-01018"],"award-info":[{"award-number":["2022-01018"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2019-02397"],"award-info":[{"award-number":["2019-02397"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2023-00356"],"award-info":[{"award-number":["2023-00356"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007625","name":"Cure Alzheimer's Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["860197"],"award-info":[{"award-number":["860197"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.cell.2025.11.033","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T15:59:10Z","timestamp":1766591950000},"page":"7337-7354","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["The evolving landscape of Alzheimer\u2019s disease therapy: From A\u03b2 to tau"],"prefix":"10.1016","volume":"188","author":[{"given":"Jean-Philippe","family":"Courade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter U.","family":"H\u00f6glinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse","family":"Dewachter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cell.2025.11.033_bib1","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/alz.12694","article-title":"Global estimates on the number of persons across the Alzheimer's disease continuum","volume":"19","author":"Gustavsson","year":"2023","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.cell.2025.11.033_bib2","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","article-title":"Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019","volume":"7","year":"2022","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.cell.2025.11.033_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2015.56","article-title":"Alzheimer's disease","volume":"1","author":"Masters","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.cell.2025.11.033_bib4","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","article-title":"Alzheimer Disease: An Update on Pathobiology and Treatment Strategies","volume":"179","author":"Long","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.cell.2025.11.033_bib5","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer's disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cell.2025.11.033_bib6","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006189","article-title":"Neuropathological alterations in Alzheimer disease","volume":"1","author":"Serrano-Pozo","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.cell.2025.11.033_bib7","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.cell.2025.11.033_bib8","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","article-title":"A\/T\/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers","volume":"87","author":"Jack","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.cell.2025.11.033_bib9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","article-title":"Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers","volume":"12","author":"Jack","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.cell.2025.11.033_bib10","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/jamaneurol.2024.3770","article-title":"Alzheimer Disease as a Clinical-Biological Construct-An International Working Group Recommendation","volume":"81","author":"Dubois","year":"2024","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.cell.2025.11.033_bib11","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.cell.2025.11.033_bib12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nature12481","article-title":"Self-propagation of pathogenic protein aggregates in neurodegenerative diseases","volume":"501","author":"Jucker","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.cell.2025.11.033_bib13","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/jamaneurol.2019.1424","article-title":"Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study","volume":"76","author":"Hanseeuw","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.cell.2025.11.033_bib14","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.cell.2025.11.033_bib15","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/nrd2959","article-title":"Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies","volume":"8","author":"Brunden","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cell.2025.11.033_bib16","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1146\/annurev.neuro.24.1.1121","article-title":"Neurodegenerative tauopathies","volume":"24","author":"Lee","year":"2001","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.cell.2025.11.033_bib17","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/nrd.2017.155","article-title":"Tau-based therapies in neurodegeneration: opportunities and challenges","volume":"16","author":"Li","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cell.2025.11.033_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","article-title":"National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease","volume":"8","author":"Hyman","year":"2012","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.cell.2025.11.033_bib19","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","article-title":"Hallmarks of neurodegenerative diseases","volume":"186","author":"Wilson","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.cell.2025.11.033_bib20","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1212\/WNL.42.3.631","article-title":"Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease","volume":"42","author":"Arriagada","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.cell.2025.11.033_bib21","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.cell.2025.11.033_bib22","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/brain\/aww027","article-title":"Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease","volume":"139","author":"Ossenkoppele","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.cell.2025.11.033_bib23","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41582-024-00942-2","article-title":"Biomarker-based staging of Alzheimer disease: rationale and clinical applications","volume":"20","author":"Therriault","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.cell.2025.11.033_bib24","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrneurol.2018.9","article-title":"Imaging tau and amyloid-beta proteinopathies in Alzheimer disease and other conditions","volume":"14","author":"Villemagne","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.cell.2025.11.033_bib25","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41582-021-00541-5","article-title":"Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies","volume":"17","author":"Stamelou","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.cell.2025.11.033_bib26","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-022-00533-z","article-title":"Tauopathies: new perspectives and challenges","volume":"17","author":"Zhang","year":"2022","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.cell.2025.11.033_bib27","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41582-023-00883-2","article-title":"Tau-targeting therapies for Alzheimer disease: current status and future directions","volume":"19","author":"Congdon","year":"2023","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.cell.2025.11.033_bib28","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41580-024-00753-9","article-title":"Cellular and pathological functions of tau","volume":"25","author":"Parra Bravo","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.cell.2025.11.033_bib29","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrn.2015.1","article-title":"Tau in physiology and pathology","volume":"17","author":"Wang","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.cell.2025.11.033_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-28896-3","article-title":"Tau deposition patterns are associated with functional connectivity in primary tauopathies","volume":"13","author":"Franzmeier","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cell.2025.11.033_bib31","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00401-020-02158-2","article-title":"Distribution patterns of tau pathology in progressive supranuclear palsy","volume":"140","author":"Kovacs","year":"2020","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.cell.2025.11.033_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3001694","article-title":"If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?","volume":"20","author":"Haass","year":"2022","journal-title":"PLoS Biol."},{"key":"10.1016\/j.cell.2025.11.033_bib33","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1016\/j.cell.2023.09.023","article-title":"Accelerating Alzheimer's therapeutic development: The past and future of clinical trials","volume":"186","author":"Boxer","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.cell.2025.11.033_bib34","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1016\/j.cell.2023.08.021","article-title":"Alzheimer's disease: From immunotherapy to immunoprevention","volume":"186","author":"Jucker","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.cell.2025.11.033_bib35","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nn.3028","article-title":"The toxic A\u03b2 oligomer and Alzheimer's disease: an emperor in need of clothes","volume":"15","author":"Benilova","year":"2012","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.cell.2025.11.033_bib36","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41573-022-00391-w","article-title":"The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics","volume":"21","author":"Karran","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cell.2025.11.033_bib37","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0140-6736(08)61047-8","article-title":"Will anti-amyloid therapies work for Alzheimer's disease?","volume":"372","author":"St George-Hyslop","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.cell.2025.11.033_bib38","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrneurol.2009.218","article-title":"The secretases: enzymes with therapeutic potential in Alzheimer disease","volume":"6","author":"De Strooper","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.cell.2025.11.033_bib39","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","article-title":"Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial","volume":"372","author":"Holmes","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.cell.2025.11.033_bib40","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.cell.2025.11.033_bib41","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"Van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cell.2025.11.033_bib42","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces Abeta plaques in Alzheimer's disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.cell.2025.11.033_bib43","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.cell.2025.11.033_bib44","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease","volume":"370","author":"Doody","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cell.2025.11.033_bib45","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1304839","article-title":"Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cell.2025.11.033_bib46","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","article-title":"Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization","volume":"61","author":"Orgogozo","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.cell.2025.11.033_bib47","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0896-6273(03)00294-0","article-title":"Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease","volume":"38","author":"Hock","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.cell.2025.11.033_bib48","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev.neuro.31.060407.125529","article-title":"Active and passive immunotherapy for neurodegenerative disorders","volume":"31","author":"Brody","year":"2008","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.cell.2025.11.033_bib49","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/brain\/awz346","article-title":"Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology","volume":"143","author":"Blennow","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.cell.2025.11.033_bib50","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1093\/brain\/awy059","article-title":"Longitudinal tau PET in ageing and Alzheimer's disease","volume":"141","author":"Jack","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.cell.2025.11.033_bib51","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1093\/brain\/awad189","article-title":"Tau protein spreads through functionally connected neurons in Alzheimer's disease: a combined MEG\/PET study","volume":"146","author":"Schoonhoven","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.cell.2025.11.033_bib52","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/brain\/aww023","article-title":"Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages","volume":"139","author":"Schwarz","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.cell.2025.11.033_bib53","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","article-title":"CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis","volume":"15","author":"Olsson","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.cell.2025.11.033_bib54","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S1474-4422(22)00168-5","article-title":"Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials","volume":"21","author":"Ossenkoppele","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.cell.2025.11.033_bib55","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-021-00430-x","article-title":"Moving fluid biomarkers for Alzheimer's disease from research tools to routine clinical diagnostics","volume":"16","author":"Zetterberg","year":"2021","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.cell.2025.11.033_bib56","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.21610","article-title":"Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects","volume":"65","author":"Shaw","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.cell.2025.11.033_bib57","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.2010.2008","article-title":"Use of florbetapir-PET for imaging beta-amyloid pathology","volume":"305","author":"Clark","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.cell.2025.11.033_bib58","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1038\/s41591-025-03617-7","article-title":"Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer's disease","volume":"31","author":"Horie","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2025.11.033_bib59","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14397","article-title":"Plasma p-tau immunoassays in clinical research for Alzheimer's disease","volume":"21","author":"Teunissen","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.cell.2025.11.033_bib60","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer's disease","volume":"367","author":"Bateman","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cell.2025.11.033_bib61","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70078","article-title":"Insights into pathophysiology, biomarkers, and therapeutics in tauopathies: proceedings of the Tau2024 Global Conference","volume":"21","author":"Frost","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.cell.2025.11.033_bib62","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/brain\/awaa373","article-title":"CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer's disease","volume":"144","author":"Horie","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.cell.2025.11.033_bib63","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/s41591-023-02443-z","article-title":"CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease","volume":"29","author":"Horie","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2025.11.033_bib64","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.tins.2010.04.003","article-title":"The propagation of prion-like protein inclusions in neurodegenerative diseases","volume":"33","author":"Goedert","year":"2010","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.cell.2025.11.033_bib65","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1146\/annurev-neuro-072116-031153","article-title":"Propagation of Tau Aggregates and Neurodegeneration","volume":"40","author":"Goedert","year":"2017","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.cell.2025.11.033_bib66","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41593-018-0238-6","article-title":"Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases","volume":"21","author":"Jucker","year":"2018","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.cell.2025.11.033_bib67","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nrn2194","article-title":"Tau-mediated neurodegeneration in Alzheimer's disease and related disorders","volume":"8","author":"Ballatore","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.cell.2025.11.033_bib68","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00401-019-02087-9","article-title":"From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy","volume":"139","author":"Colin","year":"2020","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.cell.2025.11.033_bib69","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41586-021-03911-7","article-title":"Structure-based classification of tauopathies","volume":"598","author":"Shi","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.cell.2025.11.033_bib70","article-title":"Alzheimer's disease drug development pipeline: 2025","volume":"11","author":"Cummings","year":"2025","journal-title":"Alzheimers Dement. (N Y)"},{"key":"10.1016\/j.cell.2025.11.033_bib71","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1038\/s41594-025-01498-5","article-title":"Tau filaments with the Alzheimer fold in human MAPT mutants V337M and R406W","volume":"32","author":"Qi","year":"2025","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.cell.2025.11.033_bib72","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41586-023-06437-2","article-title":"Molecular pathology of neurodegenerative diseases by cryo-EM of amyloids","volume":"621","author":"Scheres","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.cell.2025.11.033_bib73","doi-asserted-by":"crossref","DOI":"10.1126\/science.1255555","article-title":"NEURODEGENERATION. Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled Abeta, tau, and alpha-synuclein","volume":"349","author":"Goedert","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.cell.2025.11.033_bib74","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00401-015-1413-4","article-title":"Templated misfolding of Tau by prion-like seeding along neuronal connections impairs neuronal network function and associated behavioral outcomes in Tau transgenic mice","volume":"129","author":"Stancu","year":"2015","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.cell.2025.11.033_bib75","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/ncb1901","article-title":"Transmission and spreading of tauopathy in transgenic mouse brain","volume":"11","author":"Clavaguera","year":"2009","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.cell.2025.11.033_bib76","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.neuron.2016.09.055","article-title":"Tau Prion Strains Dictate Patterns of Cell Pathology, Progression Rate, and Regional Vulnerability In Vivo","volume":"92","author":"Kaufman","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.cell.2025.11.033_bib77","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.neuron.2014.04.047","article-title":"Distinct tau prion strains propagate in cells and mice and define different tauopathies","volume":"82","author":"Sanders","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.cell.2025.11.033_bib78","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41591-020-0938-9","article-title":"Tau molecular diversity contributes to clinical heterogeneity in Alzheimer's disease","volume":"26","author":"Dujardin","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2025.11.033_bib79","doi-asserted-by":"crossref","DOI":"10.1186\/s40478-017-0488-7","article-title":"What is the evidence that tau pathology spreads through prion-like propagation?","volume":"5","author":"Mudher","year":"2017","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.cell.2025.11.033_bib80","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.neuron.2018.02.015","article-title":"Tau Kinetics in Neurons and the Human Central Nervous System","volume":"97","author":"Sato","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/j.cell.2025.11.033_bib81","doi-asserted-by":"crossref","first-page":"10039","DOI":"10.1021\/bi1016233","article-title":"Preparation and characterization of neurotoxic tau oligomers","volume":"49","author":"Lasagna-Reeves","year":"2010","journal-title":"Biochemistry"},{"key":"10.1016\/j.cell.2025.11.033_bib82","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1326-6-39","article-title":"Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice","volume":"6","author":"Lasagna-Reeves","year":"2011","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.cell.2025.11.033_bib83","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.trci.2017.05.002","article-title":"Alzheimer's disease drug development pipeline: 2017","volume":"3","author":"Cummings","year":"2017","journal-title":"Alzheimers Dement. (N Y)"},{"key":"10.1016\/j.cell.2025.11.033_bib84","article-title":"Alzheimer's disease drug development pipeline: 2023","volume":"9","author":"Cummings","year":"2023","journal-title":"Alzheimers Dement. (N Y)"},{"key":"10.1016\/j.cell.2025.11.033_bib85","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41591-021-01465-9","article-title":"Tau-targeting antibody therapies: too late, wrong epitope or wrong target?","volume":"27","author":"Jabbari","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2025.11.033_bib86","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","article-title":"Tau-targeting therapies for Alzheimer disease","volume":"14","author":"Congdon","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.cell.2025.11.033_bib87","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag0481","article-title":"Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy","volume":"9","author":"DeVos","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cell.2025.11.033_bib88","doi-asserted-by":"crossref","first-page":"12887","DOI":"10.1523\/JNEUROSCI.2107-13.2013","article-title":"Antisense reduction of tau in adult mice protects against seizures","volume":"33","author":"DeVos","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.cell.2025.11.033_bib89","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2174\/156652321405140926160602","article-title":"Tau silencing by siRNA in the P301S mouse model of tauopathy","volume":"14","author":"Xu","year":"2014","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.cell.2025.11.033_bib90","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/acn3.52264","article-title":"Tofersen treatment leads to sustained stabilization of disease in SOD1 ALS in a \u201creal-world\u201d setting","volume":"12","author":"Smith","year":"2025","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.cell.2025.11.033_bib91","unstructured":"FDA. Tofersen. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-amyotrophic-lateral-sclerosis-associated-mutation-sod1-gene."},{"key":"10.1016\/j.cell.2025.11.033_bib92","doi-asserted-by":"crossref","DOI":"10.1126\/science.aec7429","article-title":"Kaiser J. In a first, a gene therapy seems to slow Huntington disease","volume":"390","author":"Kaiser","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.cell.2025.11.033_bib93","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1126\/science.354.6318.1359","article-title":"Antisense rescues babies from killer disease","volume":"354","author":"Wadman","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.cell.2025.11.033_bib94","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cell.2025.11.033_bib95","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jamaneurol.2023.3861","article-title":"Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease: A Randomized Clinical Trial","volume":"80","author":"Edwards","year":"2023","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.cell.2025.11.033_bib96","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/s41591-023-02326-3","article-title":"Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial","volume":"29","author":"Mummery","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2025.11.033_bib97","doi-asserted-by":"crossref","first-page":"803","DOI":"10.4103\/NRR.NRR-D-23-02057","article-title":"Antisense oligonucleotides provide optimism to the therapeutic landscape for tauopathies","volume":"20","author":"Harris","year":"2025","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.cell.2025.11.033_bib98","doi-asserted-by":"crossref","DOI":"10.1038\/d41573-024-00180-7","article-title":"Anti-tau antibody stumbles in phase II Alzheimer trial","volume":"23","author":"Mullard","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cell.2025.11.033_bib101","doi-asserted-by":"crossref","first-page":"9115","DOI":"10.1523\/JNEUROSCI.2361-07.2007","article-title":"Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements","volume":"27","author":"Asuni","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.cell.2025.11.033_bib102","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00401-018-1911-2","article-title":"Epitope determines efficacy of therapeutic anti-Tau antibodies in a functional assay with human Alzheimer Tau","volume":"136","author":"Courade","year":"2018","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.cell.2025.11.033_bib103","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adj5958","article-title":"Nasal tau immunotherapy clears intracellular tau pathology and improves cognitive functions in aged tauopathy mice","volume":"16","author":"Gaikwad","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cell.2025.11.033_bib104","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb2639","article-title":"Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease","volume":"13","author":"Ayalon","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cell.2025.11.033_bib105","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/j.1471-4159.2011.07337.x","article-title":"Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain","volume":"118","author":"Boutajangout","year":"2011","journal-title":"J. Neurochem."},{"key":"10.1016\/j.cell.2025.11.033_bib106","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/brain\/awz100","article-title":"Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody","volume":"142","author":"Albert","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.cell.2025.11.033_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104707","article-title":"Advances and considerations in AD tau-targeted immunotherapy","volume":"134","author":"Bittar","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.cell.2025.11.033_bib108","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.neuron.2013.07.046","article-title":"Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo","volume":"80","author":"Yanamandra","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.cell.2025.11.033_bib109","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-41382-0","article-title":"Analysis of clinical failure of anti-tau and anti-synuclein antibodies in neurodegeneration using a quantitative systems pharmacology model","volume":"13","author":"Geerts","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cell.2025.11.033_bib110","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/s41591-021-01455-x","article-title":"Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial","volume":"27","author":"Dam","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2025.11.033_bib111","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1001\/jamaneurol.2022.1375","article-title":"Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial","volume":"79","author":"Teng","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.cell.2025.11.033_bib112","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S1474-4422(20)30489-0","article-title":"Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial","volume":"20","author":"H\u00f6glinger","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.cell.2025.11.033_bib113","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.celrep.2016.06.099","article-title":"Antibody-Mediated Targeting of Tau In Vivo Does Not Require Effector Function and Microglial Engagement","volume":"16","author":"Lee","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.cell.2025.11.033_bib114","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.semcdb.2021.12.002","article-title":"Targeting tau only extracellularly is likely to be less efficacious than targeting it both intra- and extracellularly","volume":"126","author":"Congdon","year":"2022","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.cell.2025.11.033_bib115","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.trci.2018.10.007","article-title":"A randomized, single ascending dose study of intravenous BIIB092 in healthy participants","volume":"4","author":"Qureshi","year":"2018","journal-title":"Alzheimers Dement. (N Y)"},{"key":"10.1016\/j.cell.2025.11.033_bib116","doi-asserted-by":"crossref","first-page":"P592","DOI":"10.1016\/j.jalz.2017.07.227","article-title":"O2\u201314\u201305: PRECLINICAL CHARACTERIZATION OF AN ANTIBODY [LY3303560] TARGETING AGGREGATED TAU","volume":"13","author":"Alam","year":"2017","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.cell.2025.11.033_bib117","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000208061","article-title":"Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease","volume":"102","author":"Fleisher","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.cell.2025.11.033_bib118","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3233\/JAD-150962","article-title":"Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer's Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies","volume":"51","author":"Barth\u00e9lemy","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.cell.2025.11.033_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2019.165584","article-title":"N-terminal tau truncation in the pathogenesis of Alzheimer's disease (AD): Developing a novel diagnostic and therapeutic approach","volume":"1866","author":"Amadoro","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.cell.2025.11.033_bib120","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3233\/JAD-170959","article-title":"Tau Proteolysis in the Pathogenesis of Tauopathies: Neurotoxic Fragments and Novel Biomarkers","volume":"63","author":"Quinn","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.cell.2025.11.033_bib121","doi-asserted-by":"crossref","first-page":"15317","DOI":"10.1074\/jbc.M110.209296","article-title":"Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles","volume":"286","author":"Guo","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cell.2025.11.033_bib122","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1523\/JNEUROSCI.2642-12.2013","article-title":"Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy","volume":"33","author":"Iba","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.cell.2025.11.033_bib123","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature23002","article-title":"Cryo-EM structures of tau filaments from Alzheimer's disease","volume":"547","author":"Fitzpatrick","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.cell.2025.11.033_bib124","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1074\/jbc.M114.589309","article-title":"Conformation determines the seeding potencies of native and recombinant Tau aggregates","volume":"290","author":"Falcon","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cell.2025.11.033_bib125","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ajpath.2017.01.022","article-title":"Tau Antibody Targeting Pathological Species Blocks Neuronal Uptake and Interneuron Propagation of Tau in Vitro","volume":"187","author":"Nobuhara","year":"2017","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.cell.2025.11.033_bib126","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202401704R","article-title":"High-molecular-weight oligomer tau (HMWoTau) species are dramatically increased in Braak-stage dependent manner in the frontal lobe of human brains, demonstrated by a novel oligomer Tau ELISA with a mouse monoclonal antibody (APNmAb005)","volume":"38","author":"Fukumoto","year":"2024","journal-title":"FASEB J."},{"key":"10.1016\/j.cell.2025.11.033_bib127","article-title":"Pan-tau antibody BIIB076 exhibits promising safety and biomarker profile in cynomolgus monkey toxicity study","volume":"13","author":"Czerkowizc","year":"2017","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.cell.2025.11.033_bib128","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2261509","article-title":"Delivery of the Brainshuttle\u2122 amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans","volume":"15","author":"Grimm","year":"2023","journal-title":"MAbs"},{"key":"10.1016\/j.cell.2025.11.033_bib129","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1126\/science.adp5186","article-title":"Aggregate-selective removal of pathological tau by clustering-activated degraders","volume":"385","author":"Benn","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.cell.2025.11.033_bib130","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-58383-4","article-title":"Inhibition of tau neuronal internalization using anti-tau single domain antibodies","volume":"16","author":"Danis","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cell.2025.11.033_bib131","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-025-01165-w","article-title":"Biomarker-guided decision making in clinical drug development for neurodegenerative disorders","volume":"24","author":"Cummings","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cell.2025.11.033_bib132","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1093\/brain\/awy146","article-title":"Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated","volume":"141","author":"Robinson","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.cell.2025.11.033_bib133","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13024-025-00822-3","article-title":"Alpha synuclein co-pathology is associated with accelerated amyloid-driven tau accumulation in Alzheimer's disease","volume":"20","author":"Franzmeier","year":"2025","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.cell.2025.11.033_bib134","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nrn3887","article-title":"Spreading of pathology in neurodegenerative diseases: a focus on human studies","volume":"16","author":"Brettschneider","year":"2015","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.cell.2025.11.033_bib135","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1474-4422(17)30037-6","article-title":"The prion model for progression and diversity of neurodegenerative diseases","volume":"16","author":"Stopschinski","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.cell.2025.11.033_bib136","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00401-018-01957-y","article-title":"Aggregated Tau activates NLRP3-ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology in vivo","volume":"137","author":"Stancu","year":"2019","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.cell.2025.11.033_bib137","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00401-015-1525-x","article-title":"Heterotypic seeding of Tau fibrillization by pre-aggregated Abeta provides potent seeds for prion-like seeding and propagation of Tau-pathology in vivo","volume":"131","author":"Vasconcelos","year":"2016","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.cell.2025.11.033_bib138","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s00401-016-1663-9","article-title":"Tau interactome mapping based identification of Otub1 as Tau deubiquitinase involved in accumulation of pathological Tau forms in vitro and in vivo","volume":"133","author":"Wang","year":"2017","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.cell.2025.11.033_bib139","doi-asserted-by":"crossref","first-page":"9535","DOI":"10.1073\/pnas.1301175110","article-title":"Brain homogenates from human tauopathies induce tau inclusions in mouse brain","volume":"110","author":"Clavaguera","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.cell.2025.11.033_bib140","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-15701-2","article-title":"Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease","volume":"11","author":"Vogel","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cell.2025.11.033_bib141","doi-asserted-by":"crossref","first-page":"E4376","DOI":"10.1073\/pnas.1411649111","article-title":"Proteopathic tau seeding predicts tauopathy in vivo","volume":"111","author":"Holmes","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.cell.2025.11.033_bib142","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00401-018-1855-6","article-title":"Tau seeding activity begins in the transentorhinal\/entorhinal regions and anticipates phospho-tau pathology in Alzheimer's disease and PART","volume":"136","author":"Kaufman","year":"2018","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.cell.2025.11.033_bib143","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1001\/jamaneurol.2018.2505","article-title":"Mechanisms of Cell-to-Cell Transmission of Pathological Tau: A Review","volume":"76","author":"Gibbons","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.cell.2025.11.033_bib144","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00018-019-03349-1","article-title":"Mechanisms of secretion and spreading of pathological tau protein","volume":"77","author":"Brunello","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.cell.2025.11.033_bib145","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41593-024-01801-5","article-title":"Tau filaments are tethered within brain extracellular vesicles in Alzheimer's disease","volume":"28","author":"Fowler","year":"2025","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.cell.2025.11.033_bib146","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41586-020-2156-5","article-title":"LRP1 is a master regulator of tau uptake and spread","volume":"580","author":"Rauch","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cell.2025.11.033_bib147","doi-asserted-by":"crossref","first-page":"E3138","DOI":"10.1073\/pnas.1301440110","article-title":"Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds","volume":"110","author":"Holmes","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.cell.2025.11.033_bib148","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-019-0340-6","article-title":"Targeting tauopathy with engineered tau-degrading intrabodies","volume":"14","author":"Gallardo","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.cell.2025.11.033_bib149","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcae100","article-title":"Messenger RNA-encoded antibody approach for targeting extracellular and intracellular tau","volume":"6","author":"Wongsodirdjo","year":"2024","journal-title":"Brain Commun."},{"key":"10.1016\/j.cell.2025.11.033_bib150","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41586-023-06788-w","article-title":"Disease-specific tau filaments assemble via polymorphic intermediates","volume":"625","author":"L\u00f6vestam","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.cell.2025.11.033_bib151","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41577-024-01104-7","article-title":"Neuroinflammation in Alzheimer disease","volume":"25","author":"Heneka","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cell.2025.11.033_bib152","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1474-4422(23)00247-8","article-title":"Stimulation of TREM2 with agonistic antibodies-an emerging therapeutic option for Alzheimer's disease","volume":"22","author":"Schlepckow","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.cell.2025.11.033_bib153","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S1474-4422(20)30412-9","article-title":"APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches","volume":"20","author":"Serrano-Pozo","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.cell.2025.11.033_bib154","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41577-018-0051-1","article-title":"Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight","volume":"18","author":"Shi","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cell.2025.11.033_bib155","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.neuron.2022.03.004","article-title":"ApoE Cascade Hypothesis in the pathogenesis of Alzheimer's disease and related dementias","volume":"110","author":"Martens","year":"2022","journal-title":"Neuron"},{"key":"10.1016\/j.cell.2025.11.033_bib156","doi-asserted-by":"crossref","DOI":"10.1126\/science.add6260","article-title":"Pharmacological modulation of septins restores calcium homeostasis and is neuroprotective in models of Alzheimer's disease","volume":"384","author":"Princen","year":"2024","journal-title":"Science"}],"container-title":["Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0092867425013686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0092867425013686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T11:58:58Z","timestamp":1773921538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0092867425013686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":154,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0092867425013686"],"URL":"https:\/\/doi.org\/10.1016\/j.cell.2025.11.033","relation":{},"ISSN":["0092-8674"],"issn-type":[{"value":"0092-8674","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The evolving landscape of Alzheimer\u2019s disease therapy: From A\u03b2 to tau","name":"articletitle","label":"Article Title"},{"value":"Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cell.2025.11.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}